The 6CMG antibody backbone was redesigned to target the 2VSM antigen using RFantibody, with design focused on CDR regions. AbMPNN performed inverse folding for sequence generation, while IgLM refined sequences for human-like characteristics. RoseTTAFold2 assessed structural self-consistency via RMSD metrics.
